| Dr Joseph J Langhans, PHD | |
|
10,000 Bay Pines Blvd Vamc (126), Bay Pines, FL 33744 | |
| (727) 398-6661 | |
| Not Available |
| Full Name | Dr Joseph J Langhans |
|---|---|
| Gender | Male |
| Speciality | Speech-language Pathologist |
| Location | 10,000 Bay Pines Blvd Vamc (126), Bay Pines, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144275645 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SA 1551 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph J Langhans, PHD 14077 80th Ave, Seminole, FL 33776-3312 Ph: (727) 398-4420 | Dr Joseph J Langhans, PHD 10,000 Bay Pines Blvd Vamc (126), Bay Pines, FL 33744 Ph: (727) 398-6661 |
News Archive
Surviving cancer is physically and emotionally exhausting. But for many patients, beating the disease itself is just the first hurdle. A second ordeal comes from living with the fungating tumor wounds that accompany various cancers. Aside from the pain they inflict, these wounds often emit a strong and offensive odor. Not only does going into public become potentially embarrassing, but it also can be extremely depressing when even close family members are repulsed by the smell.
In a study of older adults admitted to the hospital with influenza and other acute respiratory illnesses during the 2011-2012 flu season, functional decline was common-and for some, this decline was persistent and catastrophic.
Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.
An investigational cannabinoid therapy helped provide effective analgesia when used as an adjuvant medication for cancer patients with pain that responded poorly to opioids, according to results of a multicenter trial reported in The Journal of Pain, published by the American Pain Society.
LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.
› Verified 1 days ago
Mrs. Monica J. Bickel, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10,000 Bay Pines Blvd., Bay Pines, FL 33744 Phone: 727-398-6661 | |
Dr. Amber L Hollingsworth, PH.D., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: Vamc Bay Pines, Audiology & Speech Pathology, 10000 Bay Pines Blvd, Bay Pines, FL 33744 Phone: 727-398-6661 Fax: 727-319-1209 | |
Jacqueline Louise Geleta, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10000 Bay Pines Blvd, Bay Pines, FL 33744 Phone: 727-398-6661 |